[ad_1]
The US Food and Drug Administration (FDA) today approved a boost dose of COVID-19 vaccine by Pfizer and BioNTech for 16- and 17-year-olds after health officials urged the public to get an additional vaccine amid concerns about the new variant. Omicron.
The emergency approval, issued today by the FDA, allows the population at this age to receive the third vaccine at least six months after receiving the second vaccine, reports Reuters.
About 4.7 million 16- and 17-year-olds in the United States have been fully vaccinated, and more than 2.5 million of them received a second dose six months ago, and all U.S. adult citizens are eligible for a booster dose of three approved vaccines.
Some US scientists have expressed concern about additional vaccinations for this age group due to the increased risk of rare cases of myocardial infarction in young people, which are associated with mRNA vaccines such as Pfizer and BioNTech.
The FDA approval comes a day after these companies released data suggesting that third doses of their vaccine may be key to protection against the new strain of the corona omicron virus.
top channel
[ad_2]
Source link
